Biases in clinical trials performed for regulatory approval
Gespeichert in:
Verfasser / Beitragende:
[Jan Krouwer]
Ort, Verlag, Jahr:
2015
Enthalten in:
Accreditation and Quality Assurance, 20/5(2015-10-01), 437-439
Format:
Artikel (online)
Online Zugang:
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605466068 | ||
| 003 | CHVBK | ||
| 005 | 20210128100305.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20151001xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s00769-015-1145-0 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s00769-015-1145-0 | ||
| 100 | 1 | |a Krouwer |D Jan |u Krouwer Consulting, 26 Parks Drive, 01770, Sherborn, MA, USA |4 aut | |
| 245 | 1 | 0 | |a Biases in clinical trials performed for regulatory approval |h [Elektronische Daten] |c [Jan Krouwer] |
| 520 | 3 | |a Method comparisons are routinely performed in hospital laboratories as part of the regulatory approval process. These trials are often biased in several ways. There is often a conflict of interest bias because the hospital is paid for the trial by the manufacturer of the assay. Moreover, the trial itself is often conducted in a way that is different from routine use. The reagents selected for the trial cannot be randomly selected from all possible reagents since future reagents do not exist. Yet, future reagents often have new lots of raw materials and/or changed manufacturing procedures, which can affect assay trueness. User error is often minimized because the user chosen to perform the study receives more training then would be routinely provided. All of these factors can lead to better performance in the regulatory evaluation then performance seen after release for sale as shown by examples for glucose meters. The above biases are largely unavoidable. Steps are suggested to reduce the above biases. | |
| 540 | |a Springer-Verlag Berlin Heidelberg, 2015 | ||
| 690 | 7 | |a Method comparison |2 nationallicence | |
| 690 | 7 | |a Clinical trial |2 nationallicence | |
| 690 | 7 | |a Bias |2 nationallicence | |
| 690 | 7 | |a Regulatory approval |2 nationallicence | |
| 690 | 7 | |a FDA |2 nationallicence | |
| 773 | 0 | |t Accreditation and Quality Assurance |d Springer Berlin Heidelberg |g 20/5(2015-10-01), 437-439 |x 0949-1775 |q 20:5<437 |1 2015 |2 20 |o 769 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00769-015-1145-0 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s00769-015-1145-0 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 100 |E 1- |a Krouwer |D Jan |u Krouwer Consulting, 26 Parks Drive, 01770, Sherborn, MA, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Accreditation and Quality Assurance |d Springer Berlin Heidelberg |g 20/5(2015-10-01), 437-439 |x 0949-1775 |q 20:5<437 |1 2015 |2 20 |o 769 | ||